UOC
ALBO

UBS O'Connor’s Albireo Pharma Inc ALBO Stock Holding History

UBS O'Connor’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,401
Closed -$604K – 1034
2022
Q2 		$604K Buy
+30,401
New +$802K 0.01% 803
2013
Q3 		– Sell
-9,000
Closed -$1.13M – 590
2013
Q2 		$1.13M Buy
+9,000
New +$936K 0.02% 355

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

UBS O'Connor's ALBO Position: Q3 2022 in Review

UBS O'Connor sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 30,401 shares — an estimated $604K sold.

UBS O'Connor first reported a position in ALBO in Q2 2013 and held it in 2 quarters. The position peaked at $1.13M in Q2 2013. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

  • UBS O'Connor reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
  • UBS O'Connor sold 30,401 Albireo Pharma Inc shares in Q3 2022, an estimated $604K.
  • UBS O'Connor first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's Albireo Pharma Inc position peaked at $1.13M in Q2 2013.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.